Pulmonary fibrosis: Investigating the metabolic processes of the antifibrotic agent pirfenidone.

Sun N et al. (2018). Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI, European Respiratory Journal, DOI:10.1183/13993003.02314-2017.

The combination of pharmacological and metabolomic methods ultimately led to an improved understanding of the disease mechanisms of idiopathic pulmonary fibrosis, as well as the mechanisms of action of pirfenidone.